Grade 3 or 4 toxicities
| Patient no. . | IT rituximab dose, mg . | Doses administered, n . | Grade 3/4 adverse events . |
|---|---|---|---|
| 1 | 10 | 8 | Lymphopenia, fatigue |
| 2 | 10 | 26 | Cataract (unrelated) |
| 3 | 10 | 8 | None |
| 4 | 25 | 5 | None |
| 5 | 25 | 8 | Gait, CNIII neuropathy (possibly related) |
| 6 | 25 | 8 | Lymphopenia |
| 7 | 25 | 12 | None |
| 8 | 25 | 16 | None |
| 9 | 25 | 8 | None |
| 10 | 25 | 8 | None |
| 11 | 25 | 16 | Neutropenia |
| 12 | 25 | 22 | None |
| 13 | 25 | 8 | None |
| 14 | 25 | 4 | Muscle weakness |
| Patient no. . | IT rituximab dose, mg . | Doses administered, n . | Grade 3/4 adverse events . |
|---|---|---|---|
| 1 | 10 | 8 | Lymphopenia, fatigue |
| 2 | 10 | 26 | Cataract (unrelated) |
| 3 | 10 | 8 | None |
| 4 | 25 | 5 | None |
| 5 | 25 | 8 | Gait, CNIII neuropathy (possibly related) |
| 6 | 25 | 8 | Lymphopenia |
| 7 | 25 | 12 | None |
| 8 | 25 | 16 | None |
| 9 | 25 | 8 | None |
| 10 | 25 | 8 | None |
| 11 | 25 | 16 | Neutropenia |
| 12 | 25 | 22 | None |
| 13 | 25 | 8 | None |
| 14 | 25 | 4 | Muscle weakness |